BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer
Dabrafenib in combination with trametinib was well tolerated and resulted in substantial clinical benefit, with notable PFS and sustained OS, even as a second-line treatment, in patients diagnosed with metastatic, progressive BRAF V600E-mutated, RAI-refractory thyroid cancer.
Authors
- Aron Popovtzer (ORCID: https://orcid.org/0000-0003-4428-9232)
- Chana Weiss
- Assaf Moore (ORCID: https://orcid.org/0000-0002-1502-3729)
- Gideon Y. Bachar (ORCID: https://orcid.org/0009-0005-6231-8975)
- Hagit Shoffel‐Havakuk (ORCID: https://orcid.org/0000-0002-4704-2940)
- Tara Coreanu
- Inbar Finkel
- Yasmin Korzets (ORCID: https://orcid.org/0000-0001-9281-1617)
- Eyal Robenshtok (ORCID: https://orcid.org/0000-0002-6268-4212)
- Jobran Mansour
Institutions
- Tel Aviv Sourasky Medical Center (IL)
- Hadassah Medical Center (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Archives of Endocrinology and Metabolism
- Published
- 2025-01-01
- DOI
- https://doi.org/10.20945/2359-4292-2025-0127
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00